Global Cell and Gene Therapy Third-Party Logistics Market to Reach US$ 20.98 Billion by 2033

Global Cell and Gene Therapy Third-Party Logistics Market Analysis

The global cell and gene therapy third-party logistics market is projected to grow significantly, reaching approximately US$ 20.98 billion by 2033 from US$ 8.66 billion in 2024, expanding at a CAGR of 10.33% between 2025 and 2033. This growth is primarily driven by rapid technological advancements in cold chain logistics, the increasing number of clinical trials and regulatory approvals, and the rising adoption of personalized medicine. As healthcare shifts toward patient-specific treatments, demand for highly specialized logistics solutions has increased. The transition from traditional therapies to individualized treatment approaches is reshaping supply chain requirements, encouraging innovation and investment in advanced logistics infrastructure tailored to sensitive biological materials.

Cell and Gene Therapy Third-Party Logistics Market Overview

The global CGT third-party logistics market is experiencing robust expansion due to the growing emphasis on personalized medicine and continuous technological innovation. Cell and gene therapies involve highly sensitive biological materials, such as live cells and viral vectors, which require strict temperature control and specialized handling throughout the supply chain. To meet these requirements, logistics providers are investing heavily in advanced cold chain systems, including cryogenic shipping solutions, ultra-low temperature storage, and real-time monitoring technologies. Strategic collaborations between therapy developers and logistics companies are becoming increasingly common, helping streamline distribution networks and ensure timely, secure delivery. Although challenges such as regulatory complexities and infrastructure limitations remain, ongoing improvements in supply chain efficiency and patient-focused logistics are supporting sustained market growth.

Another major factor contributing to market expansion is the rising number of clinical trials and regulatory approvals for cell and gene therapies. As more therapies progress from research to commercialization, the demand for reliable and compliant transportation solutions continues to grow. Pharmaceutical and biotechnology companies are conducting multi-regional clinical studies, which require sophisticated logistics networks capable of maintaining strict temperature conditions and ensuring product integrity across long distances.

The logistics landscape is further complicated by the unique delivery requirements of CGTs, including direct-to-patient shipments and transportation to specialized treatment centers. Many of these therapies target rare or orphan diseases, often requiring delivery to remote or less accessible locations. As a result, logistics providers must offer flexible, scalable, and highly specialized solutions. The increasing number of investigational new drug (IND) applications is also intensifying the need for advanced logistics capabilities, such as customized packaging and ultra-cold storage. Overall, the rapid expansion of CGT clinical trials is driving demand for innovative and reliable third-party logistics services tailored to these complex therapies.

Request Sample Report:https://www.renub.com/request-sample-page.php?gturl=cell-and-gene-therapy-third-party-logistics-market-p.php

Refrigerated transport launches worldwide

GMR Aero Cargo & Logistics – Airside Reefer Truck Launch

·      Launched India’s first airside refrigerated truck In Jan 2026.

·      Maintains temperature from +2°C to +25°C and supports pharma, seafood, and perishables.

Innovation Thru Energy + IceBattery India – Net-Zero Cold Chain Launch

·      Introduced net-zero refrigerated transport system in Feb 2026.

·      Reduces operational costs by ~50% and eliminates diesel dependency.

Innovation Thru Energy – IceBattery Technology Deployment

·      Launched thermal energy-based refrigeration system in Feb 2026.

·      Maintains temperature even during power failures and transit delays.

Western Railway – Refrigerated Train Launch

·      First dedicated refrigerated train launched in Nov 2025 in Gujarat.

·      Carried 1,061 tonnes of perishable goods in its first run.

Carrier Transicold – Pulsor eCool Launch

·      Introduced all-electric refrigeration unit in Sep 2025.

·      Reduced cooling time to -18°C by ~31% faster than competitors.

Celcius Logistics – Electric Reefer Fleet Rollout

·      Announced deployment of 350 electric refrigerated trucks in Oct 2025.

·      Investment: ₹100 crore (~USD 12M) for green cold logistics.

TVS Interfleet – Refrigerated Body Line Launch

·      Launched new refrigerated truck body systems in Aug 2025.

·      Focus: improved thermal efficiency and reduced operating costs.

Carrier Transicold – Supra A & Citimax D Units

·      Unveiled next-gen refrigeration units at REFCOLD in Oct 2024.

·      Designed to operate in extreme temperatures up to 55°C.

Trends in the Cell and Gene Therapy Third-Party Logistics Market

In December 2025, SCTbio and Fortrea made a strategic collaboration agreement between the two companies to simplify development, accelerate timelines and execute advanced therapies to patients rapidly.

In December 2025, ENCell signed a memorandum of understanding (MOU) with Cell Therapies, CGT CDMO, to widen access to CGT development and manufacturing in the Asia-Pacific (APAC) region.

In March 2025, DHL announced acquisition of U.S.-based pharmaceutical logistics firm CryoPDP to enhance its capabilities in the life sciences and healthcare sector. CryoPDP specializes in temperature-controlled logistics solutions, including shipping, storage, and packaging services for pharmaceutical and biotech companies. This acquisition aims to strengthen DHL's supply chain services in the pharmaceutical industry.

In January 2025, Cardinal Health announced the launch of Advanced Therapy Connect,an industry-first integrated ordering platform designed specifically for cell and gene therapies under the Advanced Therapy Solutions division.

In August 2024, Alcura, a part of Cencora, received a Manufacturing and Importation Authorization (MIA) license from the Spanish Agency of Medicines and Medical Devices. This license allowed Alcura to offer import, storage, and QP Batch Certification services for investigational and commercial cell and gene therapy products.

Growth Drivers for the Cell and Gene Therapy Third-Party Logistics Market (Rephrased)

Rising Demand for Cell and Gene Therapies

The increasing adoption of cell and gene therapies is a major force driving growth in the biotechnology and pharmaceutical sectors. As medical science advances, there is a clear shift toward personalized treatments tailored to individual genetic profiles. These therapies often involve highly sensitive biological materials, such as live cells and viral vectors, which require specialized storage, handling, and transportation conditions. Due to their complexity and patient-specific nature, efficient and secure logistics solutions are essential. Third-party logistics (3PL) providers play a critical role by offering temperature-controlled environments, advanced tracking systems, and strict regulatory compliance. As the demand for precision medicine continues to rise, the need for sophisticated logistics infrastructure and services is expected to grow significantly.

Growing Investment in Biotech and Healthcare

Rising investments in biotechnology and healthcare are accelerating the development of innovative cell and gene therapies, thereby boosting demand for specialized logistics services. As new therapies move toward commercialization, they require complex global distribution networks capable of handling sensitive and high-value products. The growing focus on advanced and personalized treatments has increased the need for logistics solutions that can manage strict temperature requirements and biological sensitivity. To address these challenges, therapy developers are forming strategic partnerships with third-party logistics providers. These collaborations enable efficient global supply chains and ensure safe, compliant cross-border transportation. With continued investment in research and innovation, the reliance on expert logistics partners is expected to intensify, further supporting market growth.

Patient-Centric Logistics

The shift toward personalized medicine has led to a growing emphasis on patient-centric logistics models. Cell and gene therapies often require customized delivery approaches, including direct-to-patient distribution, to ensure timely and safe administration. Third-party logistics providers are adapting by implementing real-time tracking systems that offer visibility into shipment status, improving transparency and patient confidence. Additionally, companies are investing in advanced packaging solutions, precise temperature control technologies, and faster delivery systems to maintain product integrity throughout transit. This patient-focused approach not only enhances treatment outcomes but also improves the overall healthcare experience. As personalized therapies become more widespread, patient-centric logistics will play an increasingly important role in ensuring effective and reliable treatment delivery.

Country Analysis

United States Cell and Gene Therapy Third-Party Logistics Market

The United States cell and gene therapy third-party logistics (3PL) market plays a critical role in supporting the complex supply chain requirements of advanced therapies. Due to the sensitive nature of cell and gene products, logistics providers must deliver highly specialized services, including temperature-controlled transportation, secure storage, real-time monitoring, and strict regulatory compliance. These partners help manufacturers manage the challenges associated with handling live biological materials, ensuring safe and timely delivery from production facilities to treatment centers. As the demand for personalized medicine continues to grow, the need for agile, technology-driven, and compliant logistics solutions is increasing. Third-party logistics providers are becoming indispensable in enhancing the scalability, efficiency, and reliability of therapy distribution across the United States.

Germany Cell and Gene Therapy Third-Party Logistics Market

Germany’s cell and gene therapy 3PL market is a key component of its expanding biopharmaceutical sector, supported by advanced infrastructure and rigorous regulatory standards. Specialized logistics providers are essential for the safe handling and transportation of temperature-sensitive therapies such as CAR-T cells and viral vectors. Effective cold chain management, including secure storage and real-time monitoring, is critical to maintaining product integrity. The market is benefiting from a growing number of clinical trials and therapy approvals, which are increasing demand for reliable logistics solutions. Regions with strong biotech presence, such as western Germany, are leading this growth. Additionally, innovations like AI-based route optimization and advanced packaging technologies are improving operational efficiency and strengthening logistics performance.

China Cell and Gene Therapy Third-Party Logistics Market

China’s cell and gene therapy 3PL market is expanding rapidly, driven by increasing investments in biotechnology and the rising adoption of personalized medicine. The transportation of these therapies requires advanced logistics capabilities, including temperature-controlled systems, secure handling, and real-time tracking to preserve the quality of sensitive biological materials. Third-party logistics providers play a vital role in managing complex supply chains and navigating regulatory frameworks. Technological advancements, such as AI-powered route planning and IoT-enabled tracking systems, are further enhancing efficiency and reliability. As China continues to strengthen its position in the global biopharmaceutical landscape, the demand for specialized logistics services is expected to grow significantly.

Saudi Arabia Cell and Gene Therapy Third-Party Logistics Market

Saudi Arabia’s cell and gene therapy 3PL market is developing rapidly, supported by the country’s strategic vision to become a global biotechnology hub by 2040. Government initiatives, particularly under Vision 2030, are driving investments in biopharmaceutical infrastructure and advanced cold chain logistics. Efforts to localize gene therapy production through strategic partnerships are also reducing reliance on international supply chains. As a result, logistics providers are adopting advanced technologies such as artificial intelligence, Internet of Things (IoT), and blockchain to improve efficiency, ensure compliance, and enhance transparency. With the growing adoption of advanced therapies, the need for specialized logistics services capable of handling sensitive materials like live cells and viral vectors is increasing, ensuring safe and timely delivery across the country.

Ask Analyst for Customization in Report:https://www.renub.com/request-sample-page.php?gturl=cell-and-gene-therapy-third-party-logistics-market-p.php

Market Segments

Type

·      Clinical

·      Commercial

Product

·      Cell Therapies

·      Gene Therapies

Therapeutic Area

·      Oncology

·      Neurology

·      Cardiovascular Diseases

·      Ophthalmology

·      Infectious Diseases

·      Others

End Use

·      Biopharmaceutical Companies

·      CDMOs/CMOs

·      Others                                               

Regional Analysis

North America

·      United States

·      Canada

Europe

·      France

·      Germany

·      Italy

·      Spain

·      United Kingdom

·      Belgium

·      Netherlands

·      Turkey

Asia Pacific

·      China

·      Japan

·      India

·      Australia

·      South Korea

·      Thailand

·      Malaysia

·      Indonesia

·      New Zealand

Latin America

·      Brazil

·      Mexico

·      Argentina

Middle East & Africa

·      South Africa

·      Saudi Arabia

·      United Arab Emirates

All the Key players have been covered from 4 Viewpoints:

·      Overview

·      Key Persons

·      Recent Development & Strategies

·      Revenue Analysis

Company Analysis:

·      Cencora Corporation

·      Cardinal Health

·      McKesson Corporation

·      EVERSANA

·      Knipper Health

·      Arvato SE

·      DHL

·      Kuehne+Nagel

About the Company:

Renub Research is a Market Research and Consulting Company. We have more than 15 years of experience especially in international Business-to-Business Researches, Surveys and Consulting. We provide a wide range of business research solutions that helps companies in making better business decisions. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. Our wide clientele comprises major players in Healthcare, Travel and Tourism, Food Beverages, Power Energy, Information Technology, Telecom Internet, Chemical, Logistics Automotive, Consumer Goods Retail, Building, and Construction, Agriculture. Our core team is comprised of experienced people holding graduate, postgraduate, and Ph.D. degrees in Finance, Marketing, Human Resource, Bio-Technology, Medicine, Information Technology, Environmental Science, and many more.        

Contact Us:

Company Name: Renub Research

Contact Person: Rajat Gupta

Phone No: (D) +91-120-421-9822 (IND)

Website: https://www.renub.com/

Email: rajat@renub.com